1-(4-fluorobenzyl)-1H-indazol-3-amine | 887258-08-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 1-(4-fluorobenzyl)-1H-indazol-3-amine
• 英文别名: 1-[(4-Fluorophenyl)methyl]indazol-3-amine
• CAS: 887258-08-4
• 化学式: C₁₄H₁₂FN₃
• 分子量: 241.268
• InChiKey: YKFIZLNCZSBBFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-fluorobenzyl)-1H-indazol-3-amine 、 乙醛 在 三乙酰氧基硼氢化钠 、 溶剂黄146 、 sodium hydroxide 、 水 作用下， 以 1,1-二氯乙烷 为溶剂， 以92%的产率得到N,N-diethyl-1-[(4-fluorophenyl)methyl]-1H-indazol-3-amine
  参考文献：
  名称：

  WO2006/52190

  摘要：

  公开号：

文献信息

• [EN] COMPOUNDS AND METHODS FOR INHIBITING FASCIN<br/>[FR] COMPOSÉS ET PROCÉDÉS D'INHIBITION DE LA FASCINE
  申请人：UNIV CORNELL

  公开号：WO2015127125A1

  公开（公告）日：2015-08-27

  Provided are compounds, compositions and methods for inhibiting fascin activity or treating a condition or disorder mediated by fascin activity in a subject in need thereof.

  提供了用于抑制fascin活性或治疗受fascin活性介导的疾病或疾病的化合物、组合物和方法。
• COMPOUNDS AND METHODS FOR INHIBITING FASCIN
  申请人：Cornell University

  公开号：US20150299191A1

  公开（公告）日：2015-10-22

  Provided are compounds, compositions and methods for inhibiting fascin activity or treating a condition or disorder mediated by fascin activity in a subject in need thereof.

  提供了一种抑制fascin活性或治疗由fascin活性介导的病症或疾病的化合物、组合物和方法，以治疗需要该方法的受体。
• Compounds and methods for inhibiting fascin
  申请人：Cornell University

  公开号：US10227345B2

  公开（公告）日：2019-03-12

  Provided are compounds, compositions and methods for inhibiting fascin activity or treating a condition or disorder mediated by fascin activity in a subject in need thereof.

  本文提供了用于抑制 fascin 活性或治疗由 fascin 活性介导的疾病的化合物、组合物和方法。
• Indazole Sulphonamide Derivatives
  申请人：Santhakumar Vijayaratnam

  公开号：US20080004288A1

  公开（公告）日：2008-01-03

  Compounds of formula I or pharmaceutically acceptable salts thereof: Formula (I) wherein R 1 , R 2 , R 3 and R 8 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
• CO-THERAPIES INCLUDING A METASTASIS INHIBITOR
  申请人：NOVITA PHARMACEUTICALS, INC.

  公开号：US20200352911A1

  公开（公告）日：2020-11-12

  Provided are methods of increasing a response to a chemotherapeutic agent or an immunotherapeutic agent in a patient in need thereof, and methods of treating cancer in a patient in need thereof, comprising administering to the patient a chemotherapeutic agent or an immunotherapeutic agent and a metastasis inhibiting compound, as described in this disclosure.